Kymera Therapeutics, Inc. (KYMR)
| Market Cap | 788.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -123.83M |
| Shares Out | 51.72M |
| EPS (ttm) | -2.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 241,695 |
| Open | 16.72 |
| Previous Close | 17.43 |
| Day's Range | 15.14 - 17.11 |
| 52-Week Range | 15.12 - 69.12 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 69.62 (+356.5%) |
| Earnings Date | May 3, 2022 |
About KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-muta...
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is 69.62, which is an increase of 356.52% from the latest price.
News
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhi...
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting
Why Kymera Therapeutics Shares Are Falling Today
In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ: KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort ...
Why Kymera Therapeutics Stock Is Getting Hammered Today
The biotech upset investors today with disappointing news for its lead program.
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring
Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
Company to begin hosting quarterly calls to provide broad updates across pipeline Company to begin hosting quarterly calls to provide broad updates across pipeline
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition...
MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition in p53 wild-type tumors and led to tumor regressions in xenograft models ...
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines and...
3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch
Is it time to buy a basket of biotech stocks?
Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences
WATERTOWN, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors
WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader...
Company plans to establish Proof-of-Mechanism and -Biology in patients in immune-inflammatory and oncology indications across its three ongoing clinical programs: IRAK4, IRAKIMiD and STAT3
Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
WATERTOWN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Biotech: Interest ‘in vaccine stocks will probably wane,' strategist says
Michael Yee, Managing Director at Jefferies, discusses Adagio and its treatment for COVID-19 as well as the outlook for Moderna in 2022 on Yahoo Finance Live.
Kymera Discloses New Development Cancer Program
Kymera Therapeutics Inc (NASDAQ: KYMR) has added KT-253 to its pipeline, targeted at liquid and solid tumors. KT-253, a selective degrader of MDM2, has the potential to become a best-in-class P53 stabil...
Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Pla...
Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines, and favorabl...
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor...
Two presentations demonstrated Kymera's STAT3 degraders can reduce STAT3 expression, modify STAT3-dependent signaling, and suppress the growth of tumors in multiple preclinical models of lymphoma and so...
Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Techn...
WATERTOWN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
WATERTOWN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021
WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer's (SI...
WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel sma...
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Tops Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -64.71% and 0.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...
Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update
Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in b...